Form 4: Recursion Pharmaceuticals Director Acquires Shares Through Compensation Policy

Director Blake Borgeson acquired 1,734 shares of Recursion Pharmaceuticals Class A Common Stock as part of the company's Outside Director Compensation Policy.

Summary

• Blake Borgeson, a director at Recursion Pharmaceuticals, acquired 1,734 shares of Class A Common Stock on January 2, 2025.
• The shares were acquired as part of the company's Outside Director Compensation Policy.
• The acquisition did not involve a monetary transaction, with a price of $0 per share.
• Following the transaction, Borgeson directly owns 7,067,847 shares of Recursion Pharmaceuticals.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is a normal part of corporate operations. There is no indication of any negative or positive sentiment beyond the standard practice.

Positives

• The acquisition of shares by a director demonstrates alignment of interests with shareholders.
• The use of a compensation policy for directors is a standard corporate practice.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders such as directors acquire or dispose of company stock. It reflects standard corporate governance practices.

Comparison to Industry Standards

• The use of stock-based compensation for directors is a common practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• Companies like Moderna, BioNTech, and Regeneron also utilize similar compensation structures for their board members.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement, ensuring transparency in insider trading activities.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director interests with company performance.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Recursion Pharmaceuticals, Director, Share Acquisition, Form 4, Compensation Policy, Insider Trading, Beneficial Ownership